Navigation Links
QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
Date:4/20/2009

hine or oxycodone every 6 hours for 48 hours. The study's primary clinical endpoint was changes in the pain intensity scores from baseline for MoxDuo(TM) IR versus component doses of morphine and oxycodone alone. Secondary endpoints included: (1) pain relief and global assessment of effect; and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

In terms of reduced pain intensity scores and other related measures, the analgesic effects of 12mg/8mg MoxDuo(TM) IR were 80-100% greater than the components, morphine or oxycodone. The 6mg/4mg MoxDuo(TM) IR dose also showed similar improvements when compared to its individual components.

Significantly, the frequency of moderate to severe adverse events (including nausea, vomiting, constipation, dizziness, etc.) was 25% to 75% lower among patients on MoxDuo(TM) IR compared to those receiving equi-analgesic doses of morphine or oxycodone alone. Furthermore, patients receiving morphine or oxycodone alone were two to four times more likely to prematurely discontinue dosing than those on MoxDuo(TM) IR.

"These data indicate that MoxDuo(TM) IR has the potential to provide superior pain relief with a lower frequency and severity of side effects when compared to either morphine or oxycodone," said Holaday. "The improved tolerability profile should enable pain practitioners to prescribe higher doses of MoxDuo(TM) IR to achieve better pain relief with fewer side effects than morphine or oxycodone alone."

Additional studies evaluating MoxDuo(TM) IR versus Percocet(R) in patients with joint replacement surgery are underway, with results expected in Q3 of 2009.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
6. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
7. Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
8. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
9. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
10. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
11. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 6, 2015 Nihon University is pleased ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up with ... in Tokyo, Japan . Many ... research will present their achievements and future prospects ... industry produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... 4, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) , ... en ligne , Prendre en charge l,hypertension ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24 /CNW/ - The weight loss medication Xenical,(orlistat ... such as blood pressure, glycaemic,control and lipid profile ... and hypertension, according to a study analysis,presented at ... ,This analysis strengthens the wealth of data already ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care to ... cancer, stroke and other serious medical conditions. Screenings are affordable and accurate and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Seedstock today announced ... keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the ... conference , held at the University of California-San Diego, will explore solutions and methodologies ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... & Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) ... move toward self-sufficiency. FESCO was created especially to provide emergency services and support ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... in grant funds to support a three-year effort to reduce rates of diabetes ... be conducted in partnership with the Morehouse School of Medicine’s Prevention Research Center ...
Breaking Medicine News(10 mins):Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... Millions for Children and Adults with Autism and Other ... ... Safeway is conducting its annual,in-store fundraising and awareness campaign to bring ... Safeway,plans to raise millions of dollars to fund Easter Seals, autism ...
... Inc., the,Midwest,s premier full service egg donor, surrogate, and ... cycle., The Get a Free Egg Donor contest ... of families from all over the world entered and,submitted ... a,free egg donor cycle, a $4,500 value., Frances ...
... Elsevier, the leading publisher of scientific, technical ... that it has added three new modules to ... Procedures Consult ( www.proceduresconsult.com ), which Elsevier ... internal medicine, is an online multimedia resource that ...
... human diseases, researchers must master the details of safe ... of Philadelphia have advanced delivery techniques by creating a ... of gene therapy vectors and can be custom-designed for ... site. , In an animal study, the research team ...
... for 30 minutes during their ... ... National Start! Walking Day. The call to action is simple:,Americans should fit ... Multimedia News Release, go to:, http://www.prnewswire.com/mnr/aha/32529/ Studies reveal that American ...
... i1000SR(R) Analyzer Enhances Workflow and ... Boosts Laboratory ... (NYSE:,ABT) has introduced the ARCHITECT(R) i1000SR(R) immunochemistry analyzer,expanding its ... for labs that typically perform less than,200 immunoassay tests ...
Cached Medicine News:Health News:Safeway's In-Store Disabilities Campaign to Benefit Easter Seals 2Health News:Reproductive Assistance Inc. Gives Back to those Suffering from Infertility 2Health News:Elsevier expands Procedures Consult with emergency medicine, orthopedics and anesthesia procedures 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3Health News:Video: Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 2Health News:Video: Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 3Health News:Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment 2Health News:Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment 3
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: